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The discovery of a stem cell population in human neoplasias
has given a new impulse to the study of the origins of cancer.
The tissue compartment in which transformation first occurs
likely comprises stem cells, since these cells need to consolid-
ate the short-term and long-term requisites of tissue renewal.
Because of their unique role, stem cells have a combination of
characteristics that makes them susceptible to genetic
damage, transformation, and tumor initiation. One type of
genetic damage in particular, chromosomal instability, might
affect the stem cell compartment, because it induces an
ongoing cycle of DNA damage and alters cellular program-
ming. Here, we will discuss some of the recently described
links between SC, chromosomal instability, and carcinogenesis,
and outline some of the consequences for oncoimmunology.
Introduction
The complexity of malignant neoplasias can be appreciated with
the recent identification of an intra-tumoral hierarchy and cancer
stem cells (CSC) in different types of cancer. In the CSC
hypothesis, the terms initiation and propagation are used to assign
a function to cell types identified inside established tumors, but
these terms do not necessarily refer to the cells from which the
tumor originates. A few decades ago, the possibility that cancer
arises from a dedifferentiation of mature cells still was under
discussion.1 The characteristics of cancer described in the last
years indicate that neoplasias can be considered a true stem cell
(SC) disease.2 Whereas initial CSC theories proposed that
“primitive” (embryonic) cells could migrate throughout the body,
the identification of tissue-specific (somatic) SC has provided a
more satisfactory explanation for the origin of cancer.1
Somatic SC have to adjust their proliferation to the need for
renewal of the tissue in which they reside. In addition, SC need to
safeguard their own health and genetic integrity, in order to carry
out their task during the entire life of the organism. SC divide
asymmetrically, so each SC produces a new SC and a cell destined
for differentation termed progenitor.3 Since the genetic integrity
of cells is largely determined by the number of divisions,4 the
number of SC divisions is kept as low as possible; progenitor cells
can undergo several divisions which amplify the cell population
destined for differentiation and tissue renewal.4
In addition to a control over the number of divisions, genetic
integrity itself is monitored.5 Chromosome damage, for example
radiation-induced double strand breaks, inhibits replication of all
cell types including SC.6 In order to prevent genetic defects,
chromosomal damage of a big enough magnitude will cause the
affected cells to enter in apoptosis.5,6 Apoptotic control in SC
however cannot be too strict, since this might eliminate the self-
renewing population and endanger tissue maintenance in the
future. SC thus have the difficult task to balance the level of
proliferation for short-term and long-term tissue stability.
Most models that propose a SC basis for cancer include a partial
blockage of differentiation; an imbalance results when the rate of
proliferation exceeds the rate of differentiation and cell loss. If this
situation persist, the transient accumulation of stem or progenitor
cells might facilitate the acquisition of genetic changes, cause a
further loss of control over proliferation, and ultimately lead to
cancer (Fig. 1). Although the CSC theory is well on its way of being
generally accepted, many details still are a matter of debate. In
addition, work on integration of the CSC theory with other aspects
of oncology, for example genetics and immunology, is just starting.
Nonetheless, combining information from different theories might
illustrate the problems SC encounter when preserving the
equilibrium between short-term and long-term tissue requisites.
Here, we will discuss possible connections between chromosomal
instability and the SC theory of cancer, and briefly outline some of
the consequences for oncoimmunology.
Chromosomal Instability and Gene Dosage
Most sporadic tumors undergo a combination of numerical
and structural changes. This combination of genetic defects is
termed chromosomal instability (CIN), and is found in approxi-
mately 85% of non-hereditary carcinomas.7,8 Although CIN is
most prominent in solid tumors, CIN has also been detected in
leukemias recently.9 Other types of genomic instability, such as
microsattelite instability and the recently described chromothrip-
sis,10 are found only in a small percentage of clinical tumor
samples. Even though CIN represents the most common form of
genetic alterations in human cancer, the role of CIN in
tumorigenesis has been a matter of debate for a long time. In
contrast to basepair mutations in oncogenes and tumor suppressor
genes, which can directly influence the activity of growth-
regulating pathways,11 the gain or loss of large chromosome
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Do not distribute.fragments does not seem to stimulate cell replication. Moreover,
since the relation between aneuploidy (involving whole
chromosomes) and segmental alterations (dependent on chro-
mosome breakage) has remained obscure until recently. Many
oncologists therefore regarded CIN as a passenger phenotype for a
long time.8
The aspect of CIN that is studied in most detail, aneuploidy,
can be induced experimentally in tissue culture cells, for example
through a transient block of mitosis by spindle poisons. In the
resulting mixed diploid and aneuploid population, the diploid
cells outgrow their aneuploid counterparts, indicating that
aneuploidy itself slows the proliferation rate of cells.12,13 In
humans, additional copies of small chromosomes can be tolerated
but is associated with developmental alterations such as Down or
Edwards syndrome.14,15 Copy number changes of large chromo-
somes however are not compatible with mammalian development.
The growth-inhibiting effect of chromosome number changes is
further illustrated by gene mutations that induce aneuploidy;
homozygous deletion of genes that control the mitotic checkpoint
results in embryonic lethality in mice.16,17 Whereas treatments
or mutations that induce chromosome copy number changes
usually have a antiproliferative and therefore tumor suppressing
effect, aneuploidy also can promote tumorigenesis. Haploinsuffi-
ciency of spindle checkpoint genes (the same genes that cause
lethality when homozygously deleted) results in increased tumor
susceptibility,18,19 and aneuploidy is detected before
intragenic mutations in experimentally induced tumors.20
Also mathematical models, which do not take into account
potential effects on cellular viability, indicate that
aneuploidy is an initiating step in tumorigenesis.21
The other aspect of CIN is a combination of trans-
locations, duplications, and deletions, known together as
segmental chromosome defects. Until recently, the origin
of segmental defects remained unknown. Under experi-
mental conditions, chromosome breaks can be induced by
stalling replication forks or imposing telomere erosion.22,23
However, these mechanisms give rise to their own parti-
cular kind of genetic alteration, which are detected only in
a small proportion of tumor samples.24,25 Furthermore, the
dominant theory of telomere erosion23 is at odds with the
CSC theory because telomere length distribution in a
tissue places the most protected telomeres in SC.26 Also in
clinical tumors, telomere erosion probably plays an minor
role.27 Recent studies show that aneuploidy and segmental
defects occur together in the majority of tumors, and
probably are different aspects of a single phenomenon.28
Like aneuploidy, segmental defects can be caused by
mitotic spindle defects.29 Furthermore, the observation
that the most frequent alteration in CIN tumors are gains
and losses of whole chromosomes and chromosome arms
supports the idea that spindle defects cause the different
genetic defects in chromosomal instability30; spindle
defects not only result in missegregation of whole chromo-
somes (resulting in aneuploidy), but also generate enough
force to shear centromeric DNA during mitosis (a
phenomenon termed centromere fission) and cause
chromosome breakage.29 Chromosome breaks play an important
role in tumor initiation and progression, because they are an
obligatory intermediate in the breakage-fusion-bridge cycles that
endow cancer cells with their genetic plasticity.27 The localization
of spindle-induced chromosome breaks, adjacent to the centro-
mere, has profound effects on the fusion products that are formed
in CIN tumors. Just as any break in the DNA, the cell will try to
repair centromeric breaks as soon as possible. Rapid repair of
breaks seems especially important in the SC compartment, in
order to prevent loss of individual SC and to maintain the
capacity for tissue renewal.31 For this reason, at least some SC
have a high activity of the non-homologous end-joining repair
system.32 Although this strategy prevents the accumulation of
externally induced breaks, it also catalyzes the fusion of
chromosome arms to the ends of receptor chromosomes.33 This
combination of the preferential repair pathway in SC and
centromere fission is reflected in the number of whole arm
translocations, which are one of the most common genetic
alteration in carcinomas.27 The fusion of chromosome arms can
generate highly unstable dicentric chromosomes,27 which produce
random breaks and trigger breakage-fusion-bride cycles.34 The
fusion of chromosome arms to the end of receptor chromosomes
can therefore promote ongoing instability and theoretically spread
through the entire genome, which provides a mechanism of
genetic plasticity in tumor progression.
Figure 1. The role of stem cells in cancer. Whereas normal tissue homeostasis
requires the coordination of the proliferation of stem and progenitor cells with their
differentiation (above), cancer-inducing defects (*) are thought to inhibit stem cell
differentiation (below). The resulting accumulation of progenitor cells with a
residual capacity to proliferate allows for additional mutations (#, ≈), which promote
further tumor growth and heterogeneity. Theories that propose the dedifferentia-
tion of fully differentiated cells have lost importance in the last years.
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Irrespective of the origin of the segmental defects and
aneuploidy in CIN, the gain and loss of large genomic fragments
is accompanied by dosage effects due to copy number changes in
active genes (protein- and micro RNA-encoding genes). The
overall effect of gene dosage on cell proliferation appears to be
inhibitory; whole arm translocations of small chromosome arms,
bearing fewer genes, are more frequent than those of large
chromosome arms that harbor many genes.24 Even the presence of
an oncogene is not sufficient to break the trend of gene dosage,
although it favors local translocations.24,25 The mechanisms by
which gene dosage disturb cell proliferation are not exactly
known; surplus protein produced in aneuploid cells apparently is
degraded, because aneuploid cells are more sensitive to autophagy
and protease inhibitors than diploid cells,35 and augmented
proteasomal protein degradation increases tolerance for aneu-
ploidy in yeast.36 Since excess proteins not incorporated in
multiprotein complexes are especially susceptible to degradation,
proteolysis has an important buffering effect on subunit ratios in
protein complexes and stabilization of gene regulatory networks.
Also feedback loops that control expression levels of subunits in
multiprotein complexes contribute to the stability of regulatory
networks.37 When the various compensatory mechanisms cannot
control gene dosage, a p53-dependent pathway is activated,
resulting in cell cycle arrest and apoptosis.38,39 In conclusion, the
gains and losses of large chromosomal segments characteristic for
CIN do not directly favor an increased growth rate, but instead
seem to be a burden for proliferating cancer cells.
In most tumors, aneuploidy is not a simple acquired genetic
state but an ongoing process. Even though genes involved in
control of the mitotic checkpoint rarely are mutated in cancer,
CIN evolves from relatively simple patterns in low grade tumors
to hyperploidy and complex translocations in high grade
tumors.30 The level of segmental defects and number of
aneuploid chromosomes both correlate with the level of
malignancy. The exact mechanisms that drive cancer cells
to ever greater instability and malignancy are not exactly
known, but a likely scenario is spill over of gene dosage on
pathways that control cell proliferation and apoptosis.
Gains and losses of whole chromosomes or large segments
not only introduce copy number changes of genes, which
can be partly buffered by regulatory pathways and protein
turnover, but also changes the levels of miRNAs that affect
the stability of large groups of mRNAs.40 In contrast to
intragenic mutations which generally affect a single
regulatory network, aneuploidy-linked gene dosage has a
general effect on cell physiology.
Do SC Tolerate CIN?
Because chromosomal instability itself reduces cellular
fitness, the large percentage of tumors presenting this type
of genetic defect seems paradoxical. Still, the most widely
accpedted models include CSC that are more resistant to
genetic damage than the surrounding tumor cells (Fig. 2).
Whereas established tumors like have acquired tolerance for
the gene dosage effects associated with aneuploidy, the
initial steps in tumorigenesis however involve cells that yet have to
acquire tolerance. Thus, the cells in which cancer first develops
probably proliferate even in the presence of a low level of CIN,
thereby allowing a certain gene dosage effect. This initial gene
dosage promotes an adaptive response in the cell, and an ever
increasing tolerance for gene dosage could drive a parallel increase
in chromosomal instability, resistance to apoptosis, dedifferentia-
tion, and malignancy. Since the tumor initiating cells in cancer are
thought to belong to the SC compartment, could these cells have
an intrinsic tolerance for chromosomal instability? Although the
CSC theory implies that a normal SC acquires the initial genetic
defects that trigger tumorigenesis, no data showing transformation
of a SC in vivo is available yet.
Since the signals that connect gene dosage cell cycle arrest and
apoptosis depend on p53,38,39 signaling of other pathways through
p53 might yield clues regarding the resistance of SC against gene
dosage. Notwithstanding the general view that p53 has an
important role in apoptotic signaling, some studies report a
protective effect of p53; whereas homozygous p53 mutation in
hematopoietic SC increases resistance against high levels of
radiation, p53 proficient hematopoietic SC are more resistant to
low levels of radiation.41 Also in a model for colon cancer, p53
positive cells were more resistant to the aneuploidy-inducing
compound paclitaxel.42 These data suggest that p53 allows for low
level DNA damage without inducing apoptosis.
Although intuition dictates that the SC need most protection
against genetic damage, the role of p53 in the SC compartment
has remained unclear until recently. The asymmetric divisions
that establish functionally different daughter cells are governed by
the p53-stabilizing protein Numb.43 Numb distributes unevenly
over the daughter cells brought about by asymmetric divisions,
Figure 2. CSC and cancer therapy. In heterogeneous primary tumors, more
differentiated cells (white) have been shown to be susceptible to treatment,
such as radiation or chemotherapy. CSC (gray) however are more resistant to
currently used treatments, and might be responsible for tumor recurrence and
ongoing chromosomal instability if not eliminated efficiently. Immunological
strategies that directly target the CSC that are more resistant to classical
therapies might thus help to ensure complete eradication of cancer cells.
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but the first studies did not show if the protein was enriched in
the self-renewing or differentiating cells.44 Thus, also the faith of
p53 in the two daughter cells remained unknown. Only recently,
Numb was shown to accumulate in one of the daughter cells
together with the SC marker CD133,45 indicating that p53 is
stabilized in the self-renewing population. In clinical tumors,
expression of CD133 is indicative of a high resistance to
radiation46 and chemotherapy,47 corroborating the hypothesis of
resistant SC. The way in which p53 protects SC against genetic
damage apparently involves the induction of a transient dormant
state termed quiescence.48 In contrast to other modes of cell
cycle arrest, the correct stimuli can induce a rapid exit from
quiescence and thereby allow SC to respond to the needs of the
surrounding tissue.
An important effect of CIN, gene dosage, induces apoptosis
through the p53-dependent pathways38,39; since p53 protects
against low levels of DNA damage through quiescence, it might
also protect against some effects of gene dosage. Just as high doses
of DNA damage, however, cells cannot be protected against high
levels of gene dosage. Even though larger chromosomes bear larger
centromeric regions and thus suffer more easily from whole arm
translocations, large scale analysis of tumor samples has shown
that smaller chromosome arms are involved in more translocations
than bigger chromosome arms.24 Probably, apoptotic pathways
other than p53 respond to gene dosage, as forced differentiation
induces apoptosis irrespective of p53 status.49-51 The tolerance for
chromosome damage and gene dosage thus are determined by a
combination of SC characteristics, some of which remain to
be discovered.
SC Induction of Immune Tolerance
Although a regulatory ability has only recently been identified for
SC, there is now ample evidence that SC can act as immuno-
suppressors. The precise mechanism by which these cells suppress
the immune system remains to be elucidated, but they are
thought to participate in several pathways: (1) in prevention of
T cell activation and proliferation; (2) in apoptosis induction
in type Th1 cells; (3) in inhibition of proinflammatory cytokine
secretion.52
SC-mediated immunosuppression was observed in a rat model
of experimental autoimmune encephalomyelitis in which trans-
planted neural SC elicited an anti-inflammatory response,
reducing brain inflammation and disease severity.53 It is thought
this is achieved by the triggering of neural SC-induced T cell
apoptosis, which shifted the inflammatory process in the brain
toward a more favorable Th2 response. In vitro studies demon-
strated that mesenchymal SC are also immunosuppressive. Again
in in vivo experiments, mesenchymal SC induced peripheral
tolerance and migrated to injured tissues, where they inhibited
release of proinflammatory cytokines and promoted the survival of
damaged cells, preventing type 1 diabetes, graft-vs.-host disease,
collagen-induced arthritis, and multiple sclerosis.54 Hematopoietic
SC also appear to have the ability to sense and respond to
situations such as tissue damage, infection, and migration to sites
of immune privilege, although in a distinct manner that involves
recognition of the hematopoietic SC niche, its proximity to
regulatory T cells, and tolerance induction.55 These cells were
shown to prevent diabetes in NOD mice,56 and are currently
undergoing evaluation in clinical trials. Umbilical cord blood SC
facilitated the generation of regulatory T cells, thereby reversing
hyperglycemia in NOD mice.
Despite limitations in our current knowledge, allo- and
xenogeneic mesenchymal SC have been used experimentally to
evade host immune response and to trigger immunosuppression,
thus showing privilege in preventing rejection. This behavior
might be explained by their ability to migrate rapidly to a
damaged organ, contributing to clearance of damage following the
release of immunomodulatory molecules.54
Concluding Remarks
In the SC model, asymmetric divisions allocate one daughter cell
for self renewal, and the other for differentiation and tissue repair.
The maintenance of tissues by SC usually includes an inter-
mediate population of progenitor cells, which remain some
proliferative capacity until differentiation is complete.2 Since
centromere fission comprises two arms of a chromosome that are
connected to opposite spindle poles and segregated into different
daughter cells,27 a single centromere fission causes a genetic
alteration in a cell dedicated to self renewal and in a cell destined
for differentiation. In practice, it might be difficult (and
unnecessary) to distinguish between a “true” SC and a progenitor
cell blocked early in differentiation. Although the segregation of
chromosome arms into two daughter cells renders the question of
stem or progenitor cells less relevant, it favors the theory of a
blocked differentiation over the dedifferentiation of mature cells.
In order to perform their function in tissue renewal, SC have a
unique combination of high proliferative capacity, high tolerance
for gene dosage, and high break repair activity (Fig. 3). SC also
show immune-suppresive effects, which target antigen presenta-
tion by dendritic cells, natural killer-cell cytotoxicity, the activa-
tion of neutrophils and the acquired immune response by
inducing T-cell peripheral tolerance, in addition to a potent
tissue-protective effect through the release of anti-inflammatory,
anti-apoptotic and trophic molecules. Together with the ability of
SC to evade immune response and to regulate effector functions
of innate immune cells,57 the genetic plasticity of CSC raises
serious dificulties in developing appropriate therapeutical tools.
Even though the basic principles of CSC are only just
becoming clear, the consequences of the CSC theory are for
related fields of study are evident. Since SC are a likely origin of
cancer, CSC represent a distinct cellular population within
tumors. The identification of stemness markers such as
CD13345,46 might help to develop combined treatments to
eradicate the cells that are more resistant to chemo- and radio-
therapy. Already, some data are available on drugs that target
chromosomal instability and gene dosage.35 Specific targeting of
these therapeutic compounds to CSC might increase efficiency
and reduce secondary effects.58 The immunosuppressive effects of
SC however add an additional dimension to the CSC theory,
which might present a mayor challenge for oncoimmunologists.
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Figure 3. Stem cell characteristics favor tumor development. A combination of stem cell properties (boxes), essential for their role in tissue renewal,
contributes to the long-term accumulation of cells bearing genetic defects (arrows). A sustained mitotic rate in combination with highly active break
repair and resistance to apoptosis are important to avoid stem cell depletion. These factors however promote chromosomal instability after accidental
breakage and fusion of centromere-containing chromosome arms, resulting in the survival of genetically imbalanced cells. Elimination of cancer cells by
the immune system (dashed arrows) might be ineffective as a consequence of stem cell immunosuppressive capacity. Once chromosomal instability is
initiated, it promotes a self-amplifying cycle of gene dosage and reduced apoptosis (dotted arrows) through the duplication and deletion of genomic
segments.
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